In Re: Zetia (Ezetimibe) Antitrust Litigation

Track this case

Case Number:

2:18-md-02836

Court:

Virginia Eastern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Rebecca Beach Smith

Firms

Companies

Sectors & Industries:

September 27, 2021
Zetia Buyers Renew Class Cert. Push After 4th Circ. Snag

Dozens of direct buyers of the cholesterol drug Zetia have urged a Virginia federal judge to again certify their class status to sue Merck and Glenmark over a generic-drug delay after the Fourth Circuit reversed an earlier certification.
August 23, 2021
Zetia Drug Buyers Win Class Cert. Against Merck, Glenmark

More than a year after a magistrate judge first recommended certifying a proposed class of drug buyers in a sprawling fight with Merck and Glenmark over the delayed release of a cholesterol drug, a Virginia federal judge is granting them certification.
January 05, 2021
Merck, Glenmark Fight Zetia Class Cert. At 4th Circ.

Drugmakers Merck and Glenmark have asked the Fourth Circuit to reverse the class certification of direct buyers of cholesterol drug Zetia, stating the named plaintiffs were unfit to represent the class and the other members' circumstances did not warrant class status.
November 17, 2020
Zetia Buyers Spar With Merck, Glenmark Over Expert Witness

Merck and Glenmark squared off Tuesday against direct drug buyers in Virginia federal court over requests to preclude certain expert testimony or evidence in multidistrict litigation accusing the pair of conspiring to keep a generic version of the cholesterol drug Zetia off the market.
November 16, 2020
4th Circ. Will Fast-Track Challenge To Zetia Buyers' Class Cert.

Direct buyers of Zetia got their wish granted Monday when the Fourth Circuit agreed to speed along a challenge to their class certification in a case accusing drugmakers Merck and Glenmark of blocking a generic form of the cholesterol drug from making it to market.
November 12, 2020
Zetia Buyers Seek To Speed Up Drug Cos.' Class Cert. Appeal

In a bid to minimize delays, direct buyers of Zetia have urged the Fourth Circuit to expedite a challenge to their class certification in a case accusing drugmakers Merck and Glenmark of violating antitrust law by blocking a generic form of the cholesterol medication.
November 03, 2020
4th Circ. Says OK To Zetia Class Certification Challenge

The Fourth Circuit is going to hear a challenge mounted by pharmaceutical giants Merck and Glenmark to the certification of what they have called an "extremely small" class of drug buyers alleging the duo conspired to keep a generic version of the cholesterol drug Zetia off the market.
September 29, 2020
Merck, Glenmark Blast 'Extremely Small' Zetia Buyers' Class

Merck and Glenmark are urging the Fourth Circuit to break up what they call an "extremely small class of sophisticated corporations" accusing the drug giants of stifling generics for the cholesterol drug Zetia before their case moves ahead.
September 21, 2020
Zetia Buyers Fight Quick Appeal Of Antitrust Class Cert.

A class of direct Zetia buyers accusing Merck and Glenmark Pharmaceuticals of conspiring to keep a generic version of the cholesterol drug off the market has urged the Fourth Circuit not to allow the drug companies an immediate appeal of their certification.
September 09, 2020
Drugmakers Want Zetia 'Shortcut' Cert. Short-Circuited

A Virginia federal judge improperly certified a wildly atypical class last month when she recognized Zetia direct buyers accusing Merck and Glenmark Pharmaceuticals of conspiring to keep a generic version of the cholesterol drug off the market, the pharmaceutical companies have told the Fourth Circuit.